JOIN THE BATTLE. Beat Rare Cancers.
The Glass is Half Full is riding for Alicia Eppler who is battling a rare cancer called GIST. She has survived for the past 6 1/2 years because of three successful operations, good health, a miracle drug called Gleevec and now access to a clinical trial, DCC-2618. Gleevec is a targeted oral therapy that is a protein blocker and would not have been created without funding for rare cancer research. Alicia is indebted to her doctors at MSKCC: Gary Schwartz, Ronald DeMatteo and William Tap. She has been given a quality of life and hope. Her family and friends are her rock and support system. She has been blessed with good fortune and considers herself very Lucky!
We're raising money for rare cancer research with Cycle for Survival, and together we can change lives.
100% of every dollar you give goes directly to pioneering research led by Memorial Sloan Kettering Cancer Center (MSK).
Why this is important to us:
PATIENTS DON'T HAVE ENOUGH TREATMENT OPTIONS.
For many rare cancer patients, there is no game plan or treatment protocol—and that's a very scary thing. Cycle for Survival is committed to changing this reality through funding new clinical trials, studies, and research initiatives to propel forward progress. In its first ten years, Cycle for Survival has already raised more than $100 million—and we will not stop until we beat rare cancers.
RARE CANCERS ARE MORE COMMON THAN YOU THINK.
Roughly half of all cancer patients are fighting a rare form of the disease. These are diseases we all know: pediatric cancers, leukemia, lymphoma, thyroid, ovarian and pancreatic cancers are among the hundreds of cancer types classified as rare.
Cancer touches too many lives and hits too close to home. Together, we're united in this fight; Cycle for Survival is our way of fighting back against cancer.
What you can do:
DONATE TO SUPPORT LIFESAVING RESEARCH.
100% of every dollar you give goes directly to research efforts within six months of the events, so you can be sure your gift will have an immediate impact on the lives of rare cancer patients and their families.
Thank you for your support—let us know if you're interested in riding, too!
If you think this page contains objectionable content, please inform the system administrator